FAS and neoplasm: For instance, alterations of the N-glycosylation of Fas ligand receptor (CD95) or the O-glycosylation of Trail-receptor (TRAIL-R1 and TRAIL-R2) could modulate the tumor cell death triggered by FasL or TRAIL, respectively, thus participating in tumor escape.